VCEL Vericel Corp
Price (delayed)
$44.31
Market cap
$2.21B
P/E Ratio
211
Dividend/share
N/A
EPS
$0.21
Enterprise value
$2.23B
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured
Highlights
The EPS has soared by 200% from the previous quarter
The net income has soared by 192% QoQ
The debt rose by 12% YoY
The quick ratio has declined by 8% year-on-year and by 7% since the previous quarter
Key stats
What are the main financial stats of VCEL
Market
Valuations
Earnings
Shares outstanding
49.97M
Market cap
$2.21B
Enterprise value
$2.23B
Price to earnings (P/E)
211
Price to book (P/B)
7.49
Price to sales (P/S)
9.12
EV/EBIT
200.28
EV/EBITDA
95.71
EV/Sales
9.39
Revenue
$237.22M
Gross profit
$172.11M
Operating income
$4.52M
Net income
$10.36M
EBIT
$11.12M
EBITDA
$23.28M
Free cash flow
-$5.81M
Per share
Balance sheet
Liquidity
EPS
$0.21
EPS diluted
$0.2
Free cash flow per share
-$0.12
Book value per share
$5.92
Revenue per share
$4.86
TBVPS
$8.73
Total assets
$432.72M
Total liabilities
$140.76M
Debt
$98.85M
Equity
$291.97M
Working capital
$162.49M
Debt to equity
0.34
Current ratio
4.23
Quick ratio
3.74
Net debt/EBITDA
0.59
Margins
Efficiency
Dividend
EBITDA margin
9.8%
Gross margin
72.6%
Net margin
4.4%
Operating margin
1.9%
Return on assets
2.7%
Return on equity
4%
Return on invested capital
3.1%
Return on capital employed
2.9%
Return on sales
4.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VCEL stock price
How has the Vericel stock price performed over time
Intraday
2.84%
1 week
-4.55%
1 month
-13.61%
1 year
-13.56%
YTD
-19.3%
QTD
-0.69%
Financial performance
How have Vericel's revenue and profit performed over time
Revenue
$237.22M
Gross profit
$172.11M
Operating income
$4.52M
Net income
$10.36M
Gross margin
72.6%
Net margin
4.4%
The net income has soared by 192% QoQ
The net margin has soared by 175% QoQ
Vericel's operating income has surged by 170% YoY
Vericel's operating margin has soared by 158% YoY
Growth
What is Vericel's growth rate over time
Valuation
What is Vericel stock price valuation
P/E
211
P/B
7.49
P/S
9.12
EV/EBIT
200.28
EV/EBITDA
95.71
EV/Sales
9.39
The EPS has soared by 200% from the previous quarter
The equity rose by 29% year-on-year and by 13% since the previous quarter
VCEL's price to book (P/B) is 24% lower than its 5-year quarterly average of 9.6 and 22% lower than its last 4 quarters average of 9.3
The revenue has grown by 20% YoY and by 4.6% from the previous quarter
VCEL's price to sales (P/S) is 17% lower than its last 4 quarters average of 10.7 and 15% lower than its 5-year quarterly average of 10.4
Efficiency
How efficient is Vericel business performance
Vericel's return on assets has surged by 170% QoQ
VCEL's ROE has soared by 167% from the previous quarter
The ROS has soared by 104% from the previous quarter
The ROIC has soared by 94% since the previous quarter
Dividends
What is VCEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VCEL.
Financial health
How did Vericel financials performed over time
The total assets has increased by 22% YoY and by 11% QoQ
Vericel's total liabilities has increased by 10% YoY and by 6% from the previous quarter
The debt is 66% lower than the equity
The equity rose by 29% year-on-year and by 13% since the previous quarter
Vericel's debt to equity has decreased by 13% YoY and by 11% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.